Prognostic Factors for Patients Treated with Abiraterone

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2020 Feb 7

PMID 32025327

Citations 4

Authors

Cecilia M Alvim

Andre Mansinho

Rita S Paiva

Raquel Bras

Patricia M Semedo

Soraia Lobo-Martins

Carolina B da Ponte

Daniela Macedo

Leonor Ribeiro

Jose P Dos Reis

Isabel Fernandes

Luis Costa

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).

Methods: Retrospective evaluation of patients with mCRPC treated with AA.

Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001).

Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.

Citing Articles

The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis.

Assayag J, Kim C, Chu H, Webster J Front Oncol. 2024; 13:1194718.

PMID: 38162494 PMC: 10757350. DOI: 10.3389/fonc.2023.1194718.

Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?.

Garcia Trevijano Cabetas M, Escario-Gomez M, Gonzalez-Del Valle L, Sobrino Jimenez C, Bilbao Gomez-Martino C, Romero-Garrido J Eur J Hosp Pharm. 2021; 30(5):268-272.

PMID: 34620687 PMC: 10447949. DOI: 10.1136/ejhpharm-2021-002798.

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.

Espana S, Ochoa de Olza M, Sala N, Piulats J, Ferrandiz U, Etxaniz O Cancer Manag Res. 2020; 12:10251-10260.

PMID: 33116879 PMC: 7584507. DOI: 10.2147/CMAR.S270392.

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review.

Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M Cancer Cell Int. 2020; 20:409.

PMID: 32863768 PMC: 7448351. DOI: 10.1186/s12935-020-01508-0.

References

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Williams S . Surrogate endpoints in early prostate cancer research. Transl Androl Urol. 2018; 7(3):472-482. PMC: 6043744. DOI: 10.21037/tau.2018.05.10. View

Facchini G, Caffo O, Ortega C, DAniello C, Di Napoli M, C Cecere S . Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. Front Pharmacol. 2016; 7:123. PMC: 4870277. DOI: 10.3389/fphar.2016.00123. View

Halabi S, Armstrong A, Sartor O, de Bono J, Kaplan E, Lin C . Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013; 31(31):3944-50. PMC: 3805930. DOI: 10.1200/JCO.2013.50.3201. View

Sartor O, de Bono J . Metastatic Prostate Cancer. N Engl J Med. 2018; 378(7):645-657. DOI: 10.1056/NEJMra1701695. View

Hiroshige T, Eguchi Y, Yoshizumi O, Chikui K, Kumagai H, Kawaguchi Y . Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. Oncol Lett. 2018; 15(5):6806-6814. PMC: 5920147. DOI: 10.3892/ol.2018.8263. View

Afshar M, Al-Alloosh F, Pirrie S, Rowan C, James N, Porfiri E . Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Res. 2015; 35(2):1057-63. View

Fuerea A, Baciarello G, Patrikidou A, Albiges L, Massard C, Palma M . Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Eur J Cancer. 2016; 61:44-51. DOI: 10.1016/j.ejca.2016.03.070. View

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

10.

Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky M, Sideris S . Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016; 70(5):724-731. DOI: 10.1016/j.eururo.2016.02.055. View

11.

Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G . Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget. 2016; 7(26):40085-40094. PMC: 5129994. DOI: 10.18632/oncotarget.9485. View

12.

Schlack K, Krabbe L, Fobker M, Schrader A, Semjonow A, Boegemann M . Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. Int J Mol Sci. 2016; 17(9). PMC: 5037797. DOI: 10.3390/ijms17091520. View

13.

Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S . Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. Clin Genitourin Cancer. 2017; 15(5):520-525. DOI: 10.1016/j.clgc.2017.04.003. View

14.

Fizazi K, Scher H, Molina A, Logothetis C, Chi K, Jones R . Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10):983-92. DOI: 10.1016/S1470-2045(12)70379-0. View

15.

Gomella L, Sartor A . The current role and limitations of surrogate endpoints in advanced prostate cancer. Urol Oncol. 2013; 32(1):28.e1-9. DOI: 10.1016/j.urolonc.2012.10.001. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View